Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 72205-282

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 72205-282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sac-val-24mg-26mg-180s-cnt-lbl.jpg (Sac Val 24mg 26mg 180s Cnt Lbl)

Label for Sacubitril and Valsartan tablets, film-coated, 24 mg/26 mg strength. The label indicates an oral dosage form and a 180-tablet count. It identifies the product as prescription-only with NDC 72205-280-18, manufactured by MSN Laboratories Private Limited in India, and distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. Additional storage and handling instructions are included.*

FDA Label Image

Sac-val-24mg-26mg-60s-cnt-lbl.jpg (Sac Val 24mg 26mg 60s Cnt Lbl)

Label for Sacubitril and Valsartan film-coated tablets, strength 24 mg/26 mg, in a package of 60 tablets. The label shows the product is Rx only, manufactured by MSN Laboratories Private Limited, and distributed by Novadoz Pharmaceuticals LLC. It includes storage instructions and healthcare contact details, along with two barcodes and an NDC number 72205-280-60.*

FDA Label Image

Sac-val-49mg-51mg-180s-cnt-lbl.jpg (Sac Val 49mg 51mg 180s Cnt Lbl)

Label for Sacubitril and Valsartan Tablets, film-coated oral tablets containing 49 mg sacubitril and 51 mg valsartan. The label shows a 180 tablet count, distributed by Novadoz Pharmaceuticals LLC, with manufacturing by MSN Laboratories Private Limited, India. Storage instructions and barcodes are also visible.*

FDA Label Image

Sac-val-49mg-51mg-60s-cnt-lbl.jpg (Sac Val 49mg 51mg 60s Cnt Lbl)

Packaging label for Sacubitril and Valsartan tablets, film-coated, with the strength of 49 mg sacubitril and 51 mg valsartan. The label indicates a package of 60 tablets, Rx only, distributed by Novadoz Pharmaceuticals LLC. Storage instructions and manufacturer details (MSN Laboratories Private Limited) are also visible, along with barcodes and contact information.*

FDA Label Image

Sac-val-97mg-103mg-180s-cnt-lbl.jpg (Sac Val 97mg 103mg 180s Cnt Lbl)

Packaging label for Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablets, supplied in a package of 180 tablets. The label includes storage instructions, manufacturer MSN Laboratories Private Limited India, and distributor Novadoz Pharmaceuticals LLC. It features the NDC 72205-282-18 and a barcode.*

FDA Label Image

Sac-val-97mg-103mg-60s-cnt-lbl.jpg (Sac Val 97mg 103mg 60s Cnt Lbl)

Packaging label for Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablets, containing 60 tablets per container. The label indicates that the product is Rx only and distributed by Novadoz Pharmaceuticals LLC. It also lists MSN Laboratories Private Limited as the manufacturer. Storage instructions and usual dosage referral are included.*

FDA Label Image

Figure-1 (Sacubitril Valsartan Figure 1)

A forest plot chart showing the geometric mean ratio and 90% confidence intervals for coadministered drugs relative to reference values. The chart includes drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. Data points are marked for AUC (black circles) and Cmax (white circles) with error bars indicating variability.*

FDA Label Image

Figure-2 (Sacubitril Valsartan Figure 2)

A chart depicting geometric mean ratios with 90% confidence intervals for AUC and Cmax comparing LBQ657 and Valsartan across various population descriptions. Populations include renal impairment (mild to severe), hepatic impairment (mild to moderate), age groups, gender, and ethnicities. The x-axis shows change relative to reference values for both AUC and Cmax measurements.*

FDA Label Image

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)

A set of three Kaplan-Meier curves labeled Figure A, B, and C, each illustrating the time to cardiovascular (CV) death or heart failure hospitalizations in the PARADIGM-HF study. The charts compare Sacubitril and Valsartan with Enalapril, showing cumulative failure rates over time since randomization (days). Each chart includes risk tables for both treatments at multiple time points and hazard ratios with confidence intervals.*

FDA Label Image

Structure (Sacubitril Valsartan Structure)

Chemical structure diagrams of sacubitril and valsartan, the active ingredients in the medication Sacubitril and Valsartan tablets.*

FDA Label Image

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)

A forest plot comparing the hazard ratios for various subgroups between Sacubitril and Valsartan and Enalapril treatments. The chart includes subgroups such as age, gender, weight, race, region, NYHA class, estimated GFR, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, heart failure hospitalization, time since diagnosis, cause of heart failure, and presence of ICD. Each subgroup shows point estimates with 95% confidence intervals plotted on a horizontal axis indicating which treatment performed better.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.